大洋生物(003017) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥194,049,118.38, representing a 9.83% increase compared to ¥176,677,783.46 in the same period last year[3] - Net profit attributable to shareholders decreased by 66.56% to ¥8,431,349.53 from ¥25,212,102.44 year-on-year[3] - Basic and diluted earnings per share dropped by 66.67% to ¥0.14 from ¥0.42 in the same period last year[3] - Total operating revenue for Q1 2022 was CNY 194,049,118.38, an increase of 9.76% compared to CNY 176,677,783.46 in Q1 2021[21] - Net profit for Q1 2022 was CNY 8,431,349.53, a decrease of 66.51% from CNY 25,212,102.44 in Q1 2021[22] - The company reported a total comprehensive income of CNY 8,431,349.53 for Q1 2022, compared to CNY 25,212,102.44 in Q1 2021[22] Cash Flow - The net cash flow from operating activities was negative at -¥38,672,236.24, a decline of 1,441.19% compared to ¥2,883,434.02 in the previous year[3] - Cash flow from operating activities for Q1 2022 was negative CNY 38,672,236.24, compared to positive CNY 2,883,434.02 in Q1 2021[24] - The net cash flow from investment activities was -50,422,671.88 CNY, compared to -27,776,723.43 CNY in the previous period, indicating a decline in investment performance[25] - The net cash flow from financing activities was 7,518,397.75 CNY, an improvement from -591,000.00 CNY in the previous period, reflecting better financing management[25] - The total cash and cash equivalents at the end of the period were 50,191,666.37 CNY, down from 131,883,363.13 CNY at the beginning of the period, showing a significant decrease in liquidity[25] - The net increase in cash and cash equivalents was -81,691,696.76 CNY, compared to -25,527,073.96 CNY in the previous period, indicating worsening cash flow[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,355,019,806.57, down 1.41% from ¥1,374,346,748.42 at the end of the previous year[3] - As of March 31, 2022, the total current assets amounted to CNY 702,968,250.43, a decrease of 5.2% from CNY 742,699,144.12 at the beginning of the year[17] - The total liabilities as of March 31, 2022, were CNY 703,968,000, with short-term borrowings increasing to CNY 169,071,435.55, up from CNY 139,071,435.55 at the beginning of the year, indicating a rise of 21.6%[17] - Total liabilities as of Q1 2022 were CNY 376,106,626.88, a slight decrease from CNY 383,637,364.33 at the end of the previous period[21] - Total equity attributable to shareholders of the parent company was CNY 978,913,179.69, down from CNY 990,709,384.09 in the previous period[21] Research and Development - Research and development expenses increased by 58.35% to ¥6,594,699.94 compared to ¥4,164,681.97 in the previous year[9] - Research and development expenses for Q1 2022 were CNY 6,594,699.94, an increase of 58.00% from CNY 4,164,681.97 in Q1 2021[21] - The company is focusing on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[14] Share Repurchase - The company has repurchased a total of 587,900 shares through a special securities account, accounting for 0.9798% of the total share capital[14] - The company plans to repurchase between 1.4 million to 2.8 million shares with a budget of CNY 63 million to CNY 126 million within 12 months from the board's approval date[14] Inventory and Receivables - The accounts receivable increased to CNY 49,633,849.80 from CNY 34,263,864.88, reflecting a growth of 44.9%[16] - The inventory balance rose to CNY 183,125,642.46, up from CNY 161,607,940.34, marking an increase of 13.3%[16] Financial Management - The company experienced a 125.72% rise in financial expenses, totaling ¥1,394,897.91 due to increased bank acceptance bill discounting interest[9] - The weighted average return on equity decreased to 0.85% from 2.60% in the same period last year[3] Audit Status - The company did not undergo an audit for the first quarter report, which may affect the reliability of the financial data presented[26]